Royal Bank of Canada’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-8,948
| Closed | -$35K | – | 7306 |
|
|
2025
Q2 | $35K | Buy |
8,948
+4,178
| +88% | +$10.3K | ﹤0.01% | 6067 |
|
|
2025
Q1 | $4K | Sell |
4,770
-3,807
| -44% | -$5.28K | ﹤0.01% | 6410 |
|
|
2024
Q4 | $23K | Buy |
8,577
+3,053
| +55% | +$11.6K | ﹤0.01% | 6055 |
|
|
2024
Q3 | $29K | Buy |
5,524
+227
| +4% | +$1.18K | ﹤0.01% | 5954 |
|
|
2024
Q2 | $24K | Buy |
5,297
+3,291
| +164% | +$16K | ﹤0.01% | 5991 |
|
|
2024
Q1 | $15K | Sell |
2,006
-13,096
| -87% | -$71.9K | ﹤0.01% | 6034 |
|
|
2023
Q4 | $64K | Buy |
15,102
+9,419
| +166% | +$33.5K | ﹤0.01% | 5873 |
|
|
2023
Q3 | $24K | Buy |
5,683
+1,743
| +44% | +$8.87K | ﹤0.01% | 6116 |
|
|
2023
Q2 | $22K | Buy |
+3,940
| New | +$23.3K | ﹤0.01% | 6166 |
|
|
2022
Q4 | – | Sell |
-690
| Closed | -$2K | – | 7454 |
|
|
2022
Q3 | $2K | Buy |
690
+221
| +47% | +$800 | ﹤0.01% | 7026 |
|
|
2022
Q2 | $2K | Sell |
469
-415
| -47% | -$1.8K | ﹤0.01% | 6955 |
|
|
2022
Q1 | $4K | Sell |
884
-2,127
| -71% | -$12.5K | ﹤0.01% | 7320 |
|
|
2021
Q4 | $20K | Buy |
3,011
+1,170
| +64% | +$10.1K | ﹤0.01% | 6805 |
|
|
2021
Q3 | $21K | Buy |
1,841
+857
| +87% | +$13.4K | ﹤0.01% | 6676 |
|
|
2021
Q2 | $17K | Sell |
984
-139
| -12% | -$2.42K | ﹤0.01% | 6641 |
|
|
2021
Q1 | $22K | Buy |
1,123
+861
| +329% | +$19K | ﹤0.01% | 6368 |
|
|
2020
Q4 | $5K | Buy |
262
+252
| +2,520% | +$6K | ﹤0.01% | 6633 |
|
|
2020
Q3 | $0 | Buy |
+10
| New | +$248 | ﹤0.01% | 6767 |
|
Royal Bank of Canada's INZY Position: Q3 2025 in Review
Royal Bank of Canada sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 8,948 shares — an estimated $35K sold.
Royal Bank of Canada first reported a position in INZY in Q3 2020 and held it in 18 quarters. The position peaked at $64K in Q4 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Royal Bank of Canada reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Royal Bank of Canada sold 8,948 Inozyme Pharma shares in Q3 2025, an estimated $35K.
- Royal Bank of Canada first reported a position in Inozyme Pharma in Q3 2020 and held it in 18 quarters.
- Royal Bank of Canada's Inozyme Pharma position peaked at $64K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.